Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | HINT1 | P49773 | 2/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 5/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 2/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214160 | 1.00 | ADORA3 (0.52) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL15798626 | 1.00 | ADORA3 (0.52) | ADORA3NT5EHINT1STING1PDE3B | |
| Phosphoric Acid SCHEMBL21465165 | 0.97 | NT5E (0.50) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL16292038 | 0.92 | ADORA3 (0.49) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL16305900 | 0.92 | ADORA3 (0.49) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL18022453 | 0.92 | HINT1 (0.49) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL18072191 | 0.91 | ADORA3 (0.48) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL16214090 | 0.91 | ADORA3 (0.48) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL16858614 | 0.91 | ADORA3 (0.48) | ADORA3NT5EHINT1STING1PDE3B | |
| SCHEMBL16858617 | 0.91 | ADORA3 (0.48) | ADORA3NT5EHINT1STING1PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237106-A1 | 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION | RIBOSCIENCE LLC (US) | 2016-08-18 | — | — | US | claimed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE ARV TECH INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4727955-A1 | CYSTEINE-SUBSTITUTED RSV-F PROTEINS | GlaxoSmithKline Biologicals S.A. (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3458081-B1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | MODERNATX, INC. (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-7915232-B2 | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2011-03-29 | — | — | US | disclosed |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | MARTIN JOSEPH ARMSTRONG | 2010-01-07 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | DEVOS RENE ROBERT | 2010-01-07 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7608601-B2 | 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication | ROCHE PALO ALTO LLC (US) | 2009-10-27 | — | — | US | disclosed |
| US-7439344-B2 | Selective O-acylation of nucleosides | ROCHE PALO ALTO LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439344-B2 | Selective O-acylation of nucleosides | ROCHE PALO ALTO LLC (US) | 2008-10-21 | — | — | US | disclosed |
| US-20070066815-A1 | Selective O-acylation of nucleosides | ROCHE PALO ALTO LLC | 2007-03-22 | — | — | US | disclosed |
| US-20070066815-A1 | Selective O-acylation of nucleosides | ROCHE PALO ALTO LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097110-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, RNGTT, METTL16 | ADORA3 714/4885NT5E 773/4885HINT1 1390/4885 |
| US-20070066815-A1 | Selective O-acylation of nucleosides | NUDT1, DUT, ADAR | ADORA3 266/4885NT5E 158/4885HINT1 124/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | ADORA3 1063/4885NT5E 1006/4885HINT1 1791/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | ADORA3 90/4885NT5E 73/4885HINT1 699/4885 |
| US-20160237106-A1 | 4'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF EBOLA VIRUS RNA REPLICATION | RNMT, RNGTT, EIF2AK2 | ADORA3 342/4885NT5E 588/4885HINT1 1490/4885 |
| US-20100003213-A1 | 4'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION | NSUN2, RNGTT, RNMT | ADORA3 583/4885NT5E 399/4885HINT1 662/4885 |
| US-20260108595-A1 | BETACORONAVIRUS mRNA VACCINES | RNMT, METTL16, NSUN2 | ADORA3 1556/4885NT5E 2810/4885HINT1 3043/4885 |
| US-12622960-B2 | Varicella zoster virus (VZV) vaccine | NSUN2, RNMT, RNGTT | ADORA3 3561/4885NT5E 1935/4885HINT1 2153/4885 |
| US-20100004192-A1 | 4'-Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication | NSUN2, RNGTT, RNMT | ADORA3 583/4885NT5E 399/4885HINT1 662/4885 |
| US-20260130985-A1 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | UPF1, NSUN2, CD4 | ADORA3 2683/4885NT5E 469/4885HINT1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.